2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - R06-R09
Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Artificial Intelligence (AI), Machine Learning, Clinical Practice (Health Services and Quality), Health Economics, Quality Improvement, Quality of Care, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Study Population, Human
PAPER

736 Frailty as a prognostic factor for length of stay, intensive care unit transfer, and readmission in patients undergoing allogeneic hematopoietic cell transplantation

Sergio Rodriguez-Rodriguez, MD, MSc, Maria Queralt Salas Gay, MD, PhD2, Nihar Desai, MD, DM3, Eshrak Al-Shaibani, MD4, Igor Novitzky-Basso5, Ivan Pasic, BSc6, Auro Viswabandya, MBBS MD DM7, Fotios Michelis, MD, PhD8, Jonas Mattsson, MD PhD9, Dennis Dong Hwan Kim, MD, PhD10, Rajat Kumar, FRCPC11, Tommy Alfaro, MD, MPH12
1 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
2 Hospital Clínic De Barcelona, Barcelona, Spain
3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
4 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
5 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
6 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
7 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
8 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
9 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
10 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
11 Princess Margaret Cancer Centre, Toronto, Ontario, Canada
12 Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Frailty is correlated with adverse outcomes after allogeneic stem cell transplantation (alloHCT). However, whether frailty is associated with increased resource utilization remains unexplored. We explored the relationship between the Hematopoietic Cell Transplant Frailty Scale (HCT-FS) and early hospitalization outcomes.

We retrospectively analyzed 676 consecutive adults who underwent alloHCT between 2014 and 2025 and had complete data across the eight domains of the HCT-FS. The frailty assessment is performed as part of the standard of care in the pre transplant consultation. The scale scores eight variables, yielding a 0-10.5 point total that stratifies the patient into fit (≤1), pre frail (>1 to <5.5), or frail (≥5.5). The primary endpoints were the length of stay and cumulative incidence of discharge. The secondary endpoints included readmission and ICU admission within 100 days of alloHCT, as well as non-relapse mortality (NRM), and overall survival (OS) at 100 days and 1 year after alloHCT. Death within 100 days of alloHCT was treated as a competing risk for discharge, ICU admission, and readmission. Univariate (UVA) and multivariate (MVA) survival analyses were performed using the Cox proportional hazards regression model for OS and the Fine-Gray proportional hazards regression model for competing events (discharge, ICU admission, readmission, and NRM).

For the 676 patients included, the median age was 60 years (IQR, 46–66). The median time from frailty assessment to alloHCT was 63 days (IQR, 48–93); 109 patients (n=109/664, 16.4%) had a KPS below 90%.

According to the HCT-FS, 245 patients (36.2%) were fit, 340 (50.3%) were pre-frail, and 91 (13.5%) were frail. Most patients (457, 67.6%) received a reduced intensity conditioning regimen. Most grafts were from fully matched donors (n=569, 84.1%) and peripheral blood stem cells (n=651, 96.3%). Most patients received post-transplant cyclophosphamide-based graft-versus-host disease (GvHD) prophylaxis (n=579, 85.7%).
After a median follow-up of 38.9 months [1.3–89.4], 225 patients (33.3%) died, including 45 (6.7%) who died within 100 days of alloHCT. The 100-day and 1-year OS for the entire cohort were 93.3% [91.1–94.9] and 76.1% [72.6–79.2], respectively, with 100-day and 1-year NRM cumulative incidences of 6.1% [4.5–8.1] and 15.2% [12.5–18.1]. Among the 45 patients who died within 100 days, the main causes were infection (n=19, 42%), miscellaneous causes (n=19, 42%), acute GvHD (n=4, 9%), and relapse (n=3, 7%).

Fit patients (median 31 days, IQR 27–36) had a shorter stay than pre-frail (median 32 days, IQR 28–37) or frail patients (median 34 days, IQR 29–42) (p=0.005). Patients who were fit (94.3% [90.5–96.6]) had a higher 100-day cumulative incidence of discharge than pre-frail (93.2% [90.0–95.5]) and frail patients (86.8% [77.7–92.4]) (p=0.008)

For ICU admission, fit patients (5.7% [3.3–9.1]) had a lower 100-day cumulative incidence than pre-frail (9.1% [6.4–12.5]) and frail patients (17.7% [10.6–26.2]) (p=0.004). Compared with fit patients, frail patients had a 78% higher sub distribution hazard of ICU admission (sHR 1.78, p=0.001).

For the cumulative incidence of readmission, fit patients (25.3% [20.1–31.5]) had a lower 100-day cumulative incidence than pre-frail (33.6% [28.7–39.1]) and frail patients (41.1% [31.0–52.9]) (p=0.016). Compared with fit patients, both pre-frail (sHR 1.40, p=0.037) and frail patients (sHR 1.35, p=0.007) had higher cumulative incidences of readmission

When comparing survival outcomes by frailty status, fit patients (95.9% [92.5–97.8]) had higher 100-day OS than pre-frail (93.5% [90.3–95.7]) and frail patients (85.5% [76.4–91.3]) (p<0.001).

Compared with fit patients, pre-frail patients showed a trend toward higher NRM (sHR 1.55 [0.99–2.43], p=0.053), whereas frail patients had a significantly increased risk of NRM (sHR 1.93 [1.51–2.49], p<0.001)

In multivariable analysis, pre-frail/frail HCT-FS remained independently associated with a lower cumulative incidence of discharge (sHR 0.84, 95% CI 0.71–0.99; p=0.043), whereas HCT-CI ≥3 was the strongest independent predictor of ICU admission (sHR 2.85, p<0.001) and readmission (sHR 1.67, p=0.001).

In conclusion, pre-transplant frailty assessed by the HCT-FS was associated with greater early healthcare resource utilization after allo-HCT, particularly prolonged hospitalization and delayed discharge, while also identifying patients at increased risk of inferior survival.

 

 

 

Sergio Rodriguez-Rodriguez, MD, MSc: No relevant conflicts of interest to declare.